Long-term efficacy of intermittent peritoneal dialysis using various doses.

about

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction.

P2860

Q38669608-B65D504E-F451-4CF8-A514-5CC1F8F28B0C

P2860

Long-term efficacy of intermittent peritoneal dialysis using various doses.

Item

http://www.wikidata.org/entity/Q42324451

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@en

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@nl

type

Item

label

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@en

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@nl

prefLabel

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@en

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@nl

P1476

Long-term efficacy of intermittent peritoneal dialysis using various doses.

@en

P2093

Chun-Hua Zhou

http://www.w3.org/2001/XMLSchema#string

Ming-Xu Li

http://www.w3.org/2001/XMLSchema#string

Yong-Wu Yu

http://www.w3.org/2001/XMLSchema#string

Zhi-Yong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical research in peritoneal dialysis.

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.

Pathogenesis and management of malnutrition in chronic peritoneal dialysis patients.

Peritoneal dialysis in the 21st century: an analysis of current problems and future developments.

Ultrafiltration and dry weight-what are the cardiovascular effects?

Prevention of infectious complications in peritoneal dialysis: best demonstrated practices.

Hypervolemia, arterial hypertension and cardiovascular disease: a largely neglected problem in peritoneal dialysis.

Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases.

Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells.

P304

519-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2011.444

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230834323

http://www.w3.org/2001/XMLSchema#string

P698

22969922

http://www.w3.org/2001/XMLSchema#string

P921

renal dialysis

P932

3438724

http://www.w3.org/2001/XMLSchema#string

Long-term efficacy of intermittent peritoneal dialysis using various doses.

about

P2860

P2860

Long-term efficacy of intermittent peritoneal dialysis using various doses.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932